Key facts
- NanoMosaic’s last known valuation is $85.0M (Mar 2025).
- It has raised $48.1M across 3 recorded rounds; the latest was Seed Round ($3.0M) in Nov 2025.
- Notable investors include Insight Partners (New York), RA Capital Management, Pura Vida Investments, Time BioVentures, 28 Capital — 6 tracked in total.
- NanoMosaic has filed 1 Form D with the SEC, most recently Mar 2025 ($1.0M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for NanoMosaic
Funding rounds
3 roundsAbout NanoMosaic
Developer of a nanoneedle proteomic beta system designed to assist in proteomics. The company's platform leverages the power of nanoneedles for protein detection and quantification and offers early disease detection, prognostic monitoring and biomarker discovery on a single chip, enabling the medical and healthcare industry to accelerate biomarker discovery and validation.
- Industry
- Diagnostic Equipment
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2018
- Employees
- 16
- Website
- nanomosaicllc.com/
- Ownership
- Privately Held (backing)
NanoMosaic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NanoMosaic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NanoMosaic in its N-PORT filings yet. We sweep new filings monthly.